Getting to Goal, Getting to Goal, and Saving Lives and Saving Lives “ “ Cholesterol metabolism, Cholesterol metabolism, intake, absorption, and synthesis intake, absorption, and synthesis Timothy A. Denton, M.D., F.A.C.C. High Desert Heart Institute Victorville, CA
57
Embed
Getting to Goal, and Saving Lives “Cholesterol metabolism, intake, absorption, and synthesis Timothy A. Denton, M.D., F.A.C.C. High Desert Heart Institute.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Getting to Goal,Getting to Goal,and Saving Livesand Saving LivesGetting to Goal,Getting to Goal,and Saving Livesand Saving Lives
““Cholesterol metabolism,Cholesterol metabolism,intake, absorption, and synthesisintake, absorption, and synthesis
Timothy A. Denton, M.D., F.A.C.C.High Desert Heart Institute
Weight Changes during 2 Years According to Diet Group
Shai I et al. N Engl J Med 2008;359:229-241
Changes in Cholesterol and Triglyceride Biomarkers According to Diet Group during the Maximum Weight-Loss Phase (1 to 6 Months) and the Weight-Loss Maintenance Phase (7 to 24 Months) of the 2-
Year Intervention
Sjostrom L et al. N Engl J Med 2007;357:741-752Bariatric Surgery and Long Term Mortality in Swedish Obese Subjects
Unadjusted Cumulative Mortalityafter Bariatric Surgery
Did you hear about this trial?Randomized controlled trial - carotid intimal thickness
399 womenAge <70
Drug group192 (182)
IMT difference = 13.5% IMT change = 2.9
Placebo group205 (187)
IMT difference = 11.4% IMT change = 2.5
P = 0.287
Placebo vs atorvastatin (CASHMERE study)www.clinicaltrials.gov/ct2/show/record/NCT00163163
Kastelein J et al. N Engl J Med 2008;358:1431-1443
Enrollment and Outcomes
Another Carotid Intimal Thickness Trial (ENHANCE)
1180 FH – Heterozygotes were screened772 started run-in period
720 Randomized
357 assigned simvastatin/ezetimibe356 received the drugs29 adverse events2 lost to follow-up1 non-compliant6 withdrew consent3 other reasons322 included in primary analysis
363 assigned simvastatin/placebo361 received the drugs34 adverse events2 lost to follow-up2 non-compliant26 withdrew consent
320 included in primary analysis
Kastelein J et al. N Engl J Med 2008;358:1431-1443
Effects of Simvastatin and Combined Therapy with Simvastatin plus Ezetimibe on Levels of Cholesterol and Triglycerides
Kastelein J et al. N Engl J Med 2008;358:1431-1443
Mean ({+/-}SE) Intima-Media Thickness of the Carotid Artery during 24 Months of Therapy
2,010 Patients with AS were screenedAnd started run-in period
1,873 Randomized
944 assigned simvastatin/ezetimibe943 received the drugs198 discontinued0 lost to follow-up5 other reasons105 died944 included in primary analysis
929 assigned placebo929 received the drug170 discontinued2 lost to follow-up9 other reasons100 died929 included in primary analysis
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic StenosisSEAS Trial
Rossebo A et al. N Engl J Med 2008;10.1056
Rossebo A et al. N Engl J Med 2008;10.1056/NEJMoa0804602
Serum Low-Density Lipoprotein (LDL) Cholesterol Levels (Panel A) and the Change from Baseline in Peak Aortic-Jet Velocity (Panel B)
Rossebo A et al. N Engl J Med 2008;10.1056/NEJMoa0804602
Kaplan-Meier Curves for Primary and Secondary Outcomes and Death
SEAS trial and Cancer
• Increase in CA – p = 0.05• Not a pre-defined endpoint
• No evidence of cancer in meta-analysis“Conclusions The available results from these three trials do not provide credible evidence of any adverse effect of ezetimibe on rates of cancer.
Follow-up of longer duration will permit the balance of risks and benefits to be determined more reliably.”
Peto R, et al. NEJM www.nejm.org September 2, 2008 (10.1056/NEJMsa0806603)
Ezetimibe 10 mg Co-Administered With Ezetimibe 10 mg Co-Administered With